New therapies to promote bone healing or treat osteoporosis, arthritis and other musculoskeletal diseases require a comprehensive preclinical assessment of bone and cartilage. Suitable endpoints can be incorporated into toxicology programs to fully evaluate test articles that have an intended effect on the musculoskeletal system or to determine effects of test articles that have secondary, indirect or adverse effects.

Charles River offers services in the area of musculoskeletal research that combine established discovery and preclinical program development expertise with a host of novel bone research technologies to provide highly specialized evaluations of bone disease and bone quality. Our musculoskeletal research scientists can assess the effect of a drug in vivo or ex vivo on bone at toxicological and pharmacological doses and facilitate the interpretation of study findings to help you better design clinical trials.